Free Trial

FibroGen (FGEN) Competitors

FibroGen logo
$10.38 -0.39 (-3.62%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$10.36 -0.02 (-0.14%)
As of 10/17/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FGEN vs. IPHA, FTLF, ANRO, CRBP, MCRB, MIST, AVTX, SAVA, ELDN, and PEPG

Should you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Innate Pharma (IPHA), FitLife Brands (FTLF), Alto Neuroscience (ANRO), Corbus Pharmaceuticals (CRBP), Seres Therapeutics (MCRB), Milestone Pharmaceuticals (MIST), Avalo Therapeutics (AVTX), Cassava Sciences (SAVA), Eledon Pharmaceuticals (ELDN), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry.

FibroGen vs. Its Competitors

FibroGen (NASDAQ:FGEN) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

FibroGen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500.

Innate Pharma has a net margin of 0.00% compared to FibroGen's net margin of -3.86%.

Company Net Margins Return on Equity Return on Assets
FibroGen-3.86% N/A -27.34%
Innate Pharma N/A N/A N/A

FibroGen has higher revenue and earnings than Innate Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroGen$29.62M1.42-$47.58M-$0.38-27.32
Innate Pharma$21.77M9.17-$53.53MN/AN/A

FibroGen currently has a consensus price target of $43.00, suggesting a potential upside of 314.26%. Innate Pharma has a consensus price target of $6.50, suggesting a potential upside of 200.23%. Given FibroGen's higher possible upside, equities research analysts plainly believe FibroGen is more favorable than Innate Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FibroGen
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Innate Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

72.7% of FibroGen shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 3.1% of FibroGen shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Innate Pharma had 1 more articles in the media than FibroGen. MarketBeat recorded 1 mentions for Innate Pharma and 0 mentions for FibroGen. FibroGen's average media sentiment score of 0.00 equaled Innate Pharma'saverage media sentiment score.

Company Overall Sentiment
FibroGen Neutral
Innate Pharma Neutral

Summary

FibroGen and Innate Pharma tied by winning 5 of the 10 factors compared between the two stocks.

Get FibroGen News Delivered to You Automatically

Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FGEN vs. The Competition

MetricFibroGenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$43.57M$2.61B$6.10B$10.49B
Dividend YieldN/A57.79%5.73%4.80%
P/E Ratio-27.3222.9985.3827.13
Price / Sales1.42561.50520.13179.96
Price / CashN/A168.7137.2361.22
Price / Book-0.205.3212.236.52
Net Income-$47.58M$33.06M$3.33B$276.93M
7 Day Performance-1.61%2.29%1.18%1.93%
1 Month Performance-8.79%6.32%6.16%2.19%
1 Year Performance6.05%-5.42%60.00%35.00%

FibroGen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FGEN
FibroGen
3.9325 of 5 stars
$10.38
-3.6%
$43.00
+314.3%
+5.1%$43.57M$29.62M-27.32570Gap Up
IPHA
Innate Pharma
2.0905 of 5 stars
$2.01
-2.7%
$6.50
+224.2%
+7.7%$189.44M$21.77M0.00220
FTLF
FitLife Brands
3.5611 of 5 stars
$19.74
-2.0%
$23.00
+16.5%
+11.5%$189.23M$64.47M23.5020
ANRO
Alto Neuroscience
1.9297 of 5 stars
$6.55
-4.9%
$9.80
+49.6%
-57.3%$186.56MN/A-2.74N/A
CRBP
Corbus Pharmaceuticals
4.0435 of 5 stars
$14.52
-2.1%
$45.43
+212.9%
+3.7%$181.74MN/A-3.0540
MCRB
Seres Therapeutics
2.3824 of 5 stars
$21.00
+2.0%
$14.33
-31.7%
+12.1%$180.26M$126.32M-4.57330
MIST
Milestone Pharmaceuticals
2.6915 of 5 stars
$2.12
+0.5%
$4.50
+112.3%
+32.0%$179.34M$1M-2.5230Positive News
Gap Up
AVTX
Avalo Therapeutics
2.9775 of 5 stars
$14.00
+4.5%
$31.67
+126.2%
+47.6%$176.24M$440K0.0040News Coverage
Analyst Forecast
Short Interest ↑
SAVA
Cassava Sciences
2.4837 of 5 stars
$3.57
-1.7%
$2.00
-44.0%
-85.5%$175.36MN/A-1.4030
ELDN
Eledon Pharmaceuticals
1.8139 of 5 stars
$2.86
+0.7%
$10.00
+249.7%
+22.4%$170.06MN/A-2.4410News Coverage
Gap Up
PEPG
PepGen
3.0231 of 5 stars
$4.96
-3.3%
$8.40
+69.4%
-44.9%$168.26MN/A-1.6830Short Interest ↑

Related Companies and Tools


This page (NASDAQ:FGEN) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners